TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$150 Million


Follow-on Offering

Bookrunner, February 2015

Operator of a biopharmaceutical company. The company is focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are overlooked and under treated and can be addressed in the gastrointestinal tract.